Evidence Hub

Effect of Long - Acting Phosphodiesterase Type-5 Inhibitor - Tadalafil on Human Platelet Aggregation

Surender Deora, Surendra Kumar Verma

Acta Scientific Medical Sciences, 2022

30 participants

Abstract

Introduction: Erectile dysfunction is predominantly a vascular disease and may even be a marker for occult-cardiovascular disease.There are reports that PDE5 inhibitors inhibit platelet aggregation in animal models and only few studies presenting in vitro data of human platelet modulation by PDE type-5 inhibitor Sildenafil.The present study therefore, was planned to evaluate effect of long-acting phosphodiesterase type-5 inhibitor, tadalafil on human platelet aggregation. Methods:The study was conducted on 30 healthy male volunteers between the age of 30 to 50 years.Tadalafil 10 mg and 20 mg was given to 15 patients in each group.Blood samples were collected after four and twenty-four hours of drug administration.All blood samples were subjected for the estimation of platelet aggregation on ELVI-840 aggregometer and Omni scribe chart recorded.Results: Administration of Tadalafil has decreased platelet aggregation after 4 hrs and 24 hrs; which in both the cases was statistically significant.However, the decrease in platelet aggregation at the end of 24 hrs as compared to 4 hrs was not significant.Conclusion: Tadalafil is effective inhibitor of platelet aggregation induced by ADP and collagen.Collagen induced aggregation is more significantly blocked by Tadalafil.The dose of 20 mg is more effective in inhibition of platelet aggregation at 24 hours as compared to 10 mg.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free